Scientific Advisory Board

H. Kim Lyerly, MD, FACS
 

Training: M.D., University of California at Los Angeles, 1983 
Surgery, Duke University Medical Center, 1984-85, 1987-90
Research, Duke University Medical Center, 1985-87

Dr. Kim Lyerly is a professor in the Department of Surgery, associate professor in the Department of Pathology, and assistant professor in the Department of Immunology at Duke University Medical Center. Dr. Lyerly came to Duke in 1983 for his internship and residency and has remained ever since. He is a pioneer in the development and testing of immunologic therapies– therapies that employ the body’s own immune system to fight cancer. He is nationally and internationally recognized for developing and leading novel Phase I clinical trials that evaluated the use of dendritic cells targeting HER2/neu, CEA and RNA (ribonucleic acid) as a therapeutic vaccine to fight primary cancers as well as protect patients against recurrences. For this work, he has been awarded over 10 million dollars in peer reviewed research grant support. Dr. Lyerly serves as a consultant and advisory board member to the National Cancer Institute, WebMD, and various biotechnology and pharmaceutical companies. He co-directs the NCI sponsored workshop of cancer clinical trials and is the scientific chair of the Southwest Oncology Group Molecular Therapeutics Committee. He has published nearly 200 papers and book chapters, and has edited or co-edited 7 books. He is on the editorial board of several publications, including Surgery, Annals of Surgery, and Clinical Cancer Research.